CASE REPORT


Nosocomial Neonatal Meningitis with Acinetobacter Baumannii on Myelomeningocele: A Real Therapeutic Challenge



Adil Fouad1, *, Fatiha Bennaoui1, Nadia El Idrissi Slitine1, Nabila Soraa2, FMR Maoulainine1
1 Neonatal Intensive Care Unit, Mohamed VI University Hospital, Marrakesh, Morocco
2 Microbiology Department, Mohamed VI University Hospital, Marrakesh, Morocco


© 2018 Fouad et al.

open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

* Address correspondence to this author at the Neonatal Intensive Care Unit, Mohamed VI University Hospital, PB 2360, Ibn Sina Avenue, Marrakesh, Morocco; Tel: +212661046258; Fax: +212524300700; E-mail: adilfouad@hotmail.fr


Abstract

Imipenem-resistant Acinetobacter baumannii meningitis is a hospital-acquired infection, the treatment of which constitutes a real therapeutic challenge. In this article, together with a review of the literature, we report two cases of imipenem-resistant Acinetobacter baumannii neonatal meningitis following ruptured myelomeningocele, treated with intravenous colistin with favorable results. In recent years, Acinetobacter baumannii has become a more and more commonly described pathogen in hospital-acquired infections. However, the cases of meningitis are mainly postoperative and are still not quite frequently described in the literature. Colistin appears to be preferably administered intravenously at a dose of 100.000 IU/kg/day.

Keywords: Acinetobacter baumanii, Colistin, Intrathecally, Intravenously, Meningitis, Myelomeningocele.